Form 4: Athira Pharma CEO Mark Litton Reports Stock Transactions
SEC Form 4
Athira Pharma's CEO, Mark Litton, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- On December 31, 2024, Mark Litton, CEO of Athira Pharma, had 108,333 restricted stock units (RSUs) vest.
- Following the vesting, 25,107 shares of common stock were sold on January 2, 2025, at a weighted-average price of $0.5619 per share to cover tax withholding obligations.
- The sales occurred in multiple transactions with prices ranging from $0.5414 to $0.5939.
- After the reported transactions, Litton directly owns 242,591 shares of common stock.
- Litton also indirectly owns 6,563 shares through each of three irrevocable trusts for the benefit of his children.
- As of the report, Litton directly owns 216,667 RSUs.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider trading activity.
Future Outlook
The reporting person has remaining RSUs that will vest on June 30, 2025, and December 31, 2025, subject to continued service.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the trading activities of company executives. It's common for executives to sell shares to cover tax obligations upon the vesting of equity awards.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
- The 'sell to cover' strategy for tax obligations is a common practice among executives receiving equity compensation.
- Comparable companies like Biogen or Amgen also have similar filings when their executives trade company stock.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
- The vesting of RSUs incentivizes the CEO to continue providing service to the company.
Key Dates
| Date | Description |
|---|---|
| 10/03/2024 | Reporting person was granted 325,000 RSUs |
| 12/31/2024 | Date of earliest transaction; 108,333 RSUs vest |
| 01/02/2025 | Shares of common stock sold to cover tax obligations |
| 01/03/2025 | Date of signature for the Form 4 filing |
| 06/30/2025 | Next RSU vesting date |
| 12/31/2025 | Final RSU vesting date |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.